Summary
Stryker Corporation's third-quarter 2016 report shows robust top-line growth, with net sales increasing by 17.1% to $2.83 billion year-over-year. This growth was significantly driven by strategic acquisitions, notably Sage Products and Physio-Control, which contributed 10.5% to the sales increase. Excluding acquisitions and currency fluctuations, organic sales grew by 7.5%, indicating strong underlying demand for Stryker's products across its key segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. Profitability also saw substantial improvement, with net earnings rising 17.9% to $355 million. Diluted earnings per share (EPS) increased to $0.94 from $0.79 in the prior year. The company is actively managing its financial position, as evidenced by a significant increase in long-term debt to finance its expansion and acquisitions, alongside a strong cash flow from operations. While the company faces ongoing recall-related charges, the overall financial performance indicates a positive trajectory, bolstered by strategic M&A and solid organic growth.
Financial Highlights
51 data points| Revenue | $2.83B |
| Cost of Revenue | $960.00M |
| Gross Profit | $1.87B |
| R&D Expenses | $184.00M |
| SG&A Expenses | $1.06B |
| Operating Expenses | $1.39B |
| Operating Income | $486.00M |
| Net Income | $355.00M |
| EPS (Basic) | $0.95 |
| EPS (Diluted) | $0.94 |
| Shares Outstanding (Basic) | 374.40M |
| Shares Outstanding (Diluted) | 379.00M |
Key Highlights
- 1Net sales for the third quarter of 2016 increased by 17.1% to $2.83 billion, driven by strong performance across all segments and significant contributions from acquisitions.
- 2Acquisitions, particularly Sage Products and Physio-Control, contributed substantially to growth, accounting for 10.5% of the reported sales increase.
- 3Organic sales growth (excluding acquisitions and currency impacts) was 7.5% for the quarter, demonstrating healthy underlying demand for Stryker's products.
- 4Net earnings grew by 17.9% to $355 million, with diluted EPS increasing to $0.94 from $0.79 in the same period last year.
- 5The MedSurg segment showed exceptional growth, with net sales up 33.0% year-over-year, largely due to acquisitions.
- 6The company significantly increased its long-term debt, raising $3.5 billion in senior unsecured notes in March 2016, primarily to fund acquisitions and operations.
- 7Recall charges related to the Rejuvenate and ABG II hip stems continued, though they decreased by 62.0% to $57 million compared to the prior year's third quarter.